Artesunate inhibits the development of PVR by suppressing the TGF-β/Smad signaling pathway

Zi-Yi Wang,Yu Zhang,Jie Chen,Ling-Dan Wu,Mei-Ling Chen,Ci-Min Chen,Qi-Hua Xu
DOI: https://doi.org/10.1016/j.exer.2021.108859
IF: 3.77
2021-12-01
Experimental Eye Research
Abstract:Proliferative vitreoretinopathy (PVR) is the main cause of retinal detachment surgery failure. The epithelial-mesenchymal transition (EMT) induced by transforming growth factor (TGF-β2) plays an important role in the development of PVR. Artesunate has been widely studied as a treatment for ophthalmic diseases because of its antioxidant, anti-inflammatory, antiapoptotic and antiproliferative properties. The purpose of this study was to investigate the effects of artesunate on the TGF-β2-induced EMT in ARPE-19 cells and PVR development. We found that artesunate inhibited the proliferation and contraction of ARPE-19 cells after the EMT and the autocrine effects of TGF-β2 on ARPE-19 cells. Additionally, the levels of Smad3 and p-Smad3 were increased in clinical samples, and artesunate decreased the levels of Smad3 and p-Smad3 in ARPE-19 cells treated with TGF-β2. Artesunate also inhibited the occurrence and development of PVR in vivo. In summary, artesunate inhibits the occurrence and development of PVR by inhibiting the EMT in ARPE-19 cells.
ophthalmology
What problem does this paper attempt to address?